AIFA updates the Transparency Lists for generics

Genéricos/General | Posted 26/02/2021 post-comment0 Post your comment

The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) announced on 15 January 2021 the update of its Transparency Lists (liste di trasparenza).

28 MD002360

The substitutability and interchangeability of generics are authorized by AIFA following an evaluation of bioequivalence results. Interchangeable products are then listed in the Transparency Lists, which indicates medicines reimbursed by the Italian National Health Service (NHS) on the basis of the reference price (RP) system, with details of their RPs. Biosimilars available in Italy are not listed in the Transparency Lists and there is no automatic replacement for these products [1].

The lists of medicinal products and the relative reference prices including any reductions and paybacks have been updated in accordance with the Italian law. The lists are presented by both active ingredient and commercial name.

These lists are important, as the Italian NHS only reimburses the cost of the least expensive generics on the market. The price of drugs reimbursed by the NHS is negotiated between the marketing authorization holder and AIFA. Use of a more expensive equivalent product is only possible at the specific request of the patient with a co-payment.

In July 2020, a new decree setting new criteria and procedures for the negotiation of the price of medicinal products and related reimbursement status was published. This replaced Resolution no. 3/2001, which had governed drug pricing for the previous 19 years. In September 2020, AIFA published new draft guidelines setting out instructions for manufacturers on the preparation of the price and reimbursement dossier. The price negotiated with AIFA normally remains effective for 24 months. The contract is then automatically renewed for a further 24 months if neither party has proposed an amendment 60 days before the expiry date.

Related article
Italy Country Focus: Licensing Guidelines and Regulations

1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars policies in Italy []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Feb 26]. Available from: 

Source: AIFA, Simmons+Simmons

comment icon Comments (0)
Post your comment
Related content
Empresas farmacéuticas en Argentina
150 AA010692
Genéricos/General Posted 08/07/2022
Empresas farmacéuticas en América Latina y el Caribe
GaBIJ 2012-1 Cover V12b13PA
Genéricos/General Posted 24/06/2022
Vacuna COVID-19 producida en América Latina
25 AA011049
Genéricos/General Posted 18/03/2022
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010